MedTrace Logo

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

NCT01851642 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2025-11-06

No results posted yet for this study

Summary

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.

Conditions

  • Alpha-1 Antitrypsin Deficiency
  • AAT Deficiency
  • AATD
  • Cystic Fibrosis (CF)

Interventions

PROCEDURE

History and physical exam.

At every study visit, participant's will be asked about their medical history and will have a physical exam.

PROCEDURE

Blood draw.

At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.

PROCEDURE

Pulmonary function testing.

At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.

DRUG

Albuterol inhaler.

At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Karina Serban, MD · University of Florida, College of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-09
Primary Completion
2032-07-20
Completion
2033-07-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01851642 on ClinicalTrials.gov